Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared the successful completion of Series B and Series B+ financing rounds, totaling $100 million. The initial Series B round was led by HM with support from Yuanfeng Capital, V Capital, 6 Dimensions Capital, Agricultural Bank of China International, and the Suzhou government. The Series B+ round was led by Shengdi, an equity investment fund, with contributions from Shanghai Alliance Investment, Hefei Industry Investment, Hefei Hi-tech VC, and Suzhou Industrial Park Science and Innovation Fund.
Investment to Accelerate Clinical Pipeline and Global Trials
The proceeds from these financing rounds will be directed towards the development of Coherent’s clinical pipeline. This includes funding a pivotal Phase II study for CBP-1008 in China, Phase I/II studies for CBP-1008 in both China and the US, Phase I studies for CBP-1019 in China and the US, and IND filings for CBP-8008 (C-PROTAC) in China and the US.
Coherent’s Innovative Technology Platforms and Global Reach
Coherent Biopharma prides itself on its BEST technology platform, C-PROTAC technology platform, and chronic disease technology platform, with multiple pipelines entering global trials. The company’s Phase Ia/Ib data for CBP-1008 has been published and presented at prestigious conferences such as World ADC London, AACR, and Novel Format Conjugates, showcasing its commitment to innovation and scientific advancement in the field of drug conjugates.-Fineline Info & Tech
